Login to Your Account



Valeant, Lundbeck, J&J, GSK . . .

Epilepsy Pie Slices Will Narrow - but Players Lining Up Anyway

By Randy Osborne


Monday, August 31, 2009
Valeant Pharmaceuticals Inc.'s missed Phase IIa endpoint last week with retigabine for pain in postherpetic neuralgia leaves intact the promise proven in Phase III for epilepsy - albeit a promise somewhat limited by the dosing schedule of the potassium channel opener, subject of a lucrative year-ago deal with GlaxoSmithKline plc.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription